Evidence map›Paper›PMID 34910083›Full record

ArticleJAMA cardiology2022

Association of Complement and MAPK Activation With SARS-CoV-2-Associated Myocardial Inflammation.

Ludwig T Weckbach, Lisa Schweizer, Angelina Kraechan, Stephanie Bieber, Hellen Ishikawa-Ankerhold, Jörg Hausleiter, Steffen Massberg, Tobias Straub, Karin Klingel, Ulrich Grabmaier and 4 more

Open access · hybridAbstract read
In one paragraph

Article in JAMA cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 62 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Carbon dioxide and MAPK signalling: towards therapy for inflammation.Cell communication and signaling : CCS · 2023
    Review
  11. Myocarditis and COVID-19 related issues.Global cardiology science & practice · 2023
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Genetic Ablation ofBiomolecules · 2022
    Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Ludwig T WeckbachMedizinische Klinik und Poliklinik I, Ludwig Maximilian University Hospital Munich, Munich, Germany.
Lisa SchweizerDepartment of Proteomics and Signal Transduction, Max Plank Institute of Biochemistry, Planegg-Martinsried, Germany.
Angelina KraechanMedizinische Klinik und Poliklinik I, Ludwig Maximilian University Hospital Munich, Munich, Germany.
Stephanie BieberMedizinische Klinik und Poliklinik I, Ludwig Maximilian University Hospital Munich, Munich, Germany.
Hellen Ishikawa-AnkerholdMedizinische Klinik und Poliklinik I, Ludwig Maximilian University Hospital Munich, Munich, Germany.
Jörg HausleiterMedizinische Klinik und Poliklinik I, Ludwig Maximilian University Hospital Munich, Munich, Germany.
Steffen MassbergMedizinische Klinik und Poliklinik I, Ludwig Maximilian University Hospital Munich, Munich, Germany.
Tobias StraubCore Facility Bioinformatics, Biomedical Center, Ludwig Maximilian University Munich, Planegg-Martinsried, Germany.
Karin KlingelCardiopathology Department, Institute for Pathology and Neuropathology, Tübingen University Hospital, Tübingen, Germany.
Ulrich GrabmaierMedizinische Klinik und Poliklinik I, Ludwig Maximilian University Hospital Munich, Munich, Germany.
Maximilian ZwiebelDepartment of Proteomics and Signal Transduction, Max Plank Institute of Biochemistry, Planegg-Martinsried, Germany.
Matthias MannDepartment of Proteomics and Signal Transduction, Max Plank Institute of Biochemistry, Planegg-Martinsried, Germany.
Christian SchulzMedizinische Klinik und Poliklinik I, Ludwig Maximilian University Hospital Munich, Munich, Germany.
EMB Study Group
LMU Klinikum · DEMax Planck Institute of Biochemistry · DELudwig-Maximilians-Universität München · DEUniversity Children's Hospital Tübingen · DEUniversity of Copenhagen · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

importanceMyocardial injury is a common feature of patients with SARS-CoV-2 infection. However, the cardiac inflammatory processes associated with SARS-CoV-2 infection are not completely understood.

objectiveTo investigate the inflammatory cardiac phenotype associated with SARS-CoV-2 infection compared with viral myocarditis, immune-mediated myocarditis, and noninflammatory cardiomyopathy by integrating histologic, transcriptomic, and proteomic profiling. DESIGN, SETTING, AND

participantsThis case series was a cooperative study between the Ludwig Maximilian University Hospital Munich and the Cardiopathology Referral Center at the University of Tübingen in Germany. A cohort of 19 patients with suspected myocarditis was examined; of those, 5 patients were hospitalized with SARS-CoV-2 infection between March and May 2020. Cardiac tissue specimens from those 5 patients were compared with specimens from 5 patients with immune-mediated myocarditis, 4 patients with non-SARS-CoV-2 viral myocarditis, and 5 patients with noninflammatory cardiomyopathy, collected from January to August 2019. EXPOSURES: Endomyocardial biopsy. MAIN OUTCOMES AND MEASURES: The inflammatory cardiac phenotypes were measured by immunohistologic analysis, RNA exome capture sequencing, and mass spectrometry-based proteomic analysis of endomyocardial biopsy specimens.

resultsAmong 19 participants, the median age was 58 years (range, 37-76 years), and 15 individuals (79%) were male. Data on race and ethnicity were not collected. The abundance of CD163+ macrophages was generally higher in the cardiac tissue of patients with myocarditis, whereas lymphocyte counts were lower in the tissue of patients with SARS-CoV-2 infection vs patients with non-SARS-CoV-2 virus-associated and immune-mediated myocarditis. Among those with SARS-CoV-2 infection, components of the complement cascade, including C1q subunits (transcriptomic analysis: 2.5-fold to 3.6-fold increase; proteomic analysis: 2.0-fold to 3.4-fold increase) and serine/cysteine proteinase inhibitor clade G member 1 (transcriptomic analysis: 1.7-fold increase; proteomic analysis: 2.6-fold increase), belonged to the most commonly upregulated transcripts and differentially abundant proteins. In cardiac macrophages, the abundance of C1q was highest in SARS-CoV-2 infection. Assessment of important signaling cascades identified an upregulation of the serine/threonine mitogen-activated protein kinase pathways. CONCLUSIONS AND RELEVANCE: This case series found that the cardiac immune signature varied in inflammatory conditions with different etiologic characteristics. Future studies are needed to examine the role of these immune pathways in myocardial inflammation.

Indexed as

COVID-19MyocarditisHumansInflammationMaleProteomicsSARS-CoV-2

Identifiers

PMID34910083
PMCPMC8674808
OpenAlexW4200500230

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.